Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 6, 2005, Pages 635-646

  Cunningham, Stephen ^b   Graham, Colin ^b   Hutchinson, Michael ^b   Droogan, Aidan ^b   O'Rourke, Killian ^b   Patterson, Chris ^b   McDonnell, Gavin ^b   Hawkins, Stanley ^b   Vandenbroeck, Koen ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RECOMBINANT ALPHA INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE SEQUENCE; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SCREENING; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROMOTER REGION; UNINDEXED SEQUENCE;

EID: 28844476586     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.08.018     Document Type: Article

References (54)

1. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group Neurology 45 1995 1227 1285
2. C.F. Brosnan, C.S. Raine Mechanism of immune injury in multiple sclerosis Brain Pathol 6 1996 243 257
3. P.A. Neighbour, A.E. Miller, B.R. Bloom Interferon responses of leukocytes in multiple sclerosis Neurology 31 1981 561 566
4. L. Jacobs, J.A. O'Malley, A. Freeman, P. Reese Intrathecal interferon as treatment of multiple sclerosis. A planned multicenter study Arch Neurol 40 1983 683 686
5. The Once Weekly Interferon for MS Study Group Evidence of interferon beta-1a dose response in relapsing-remitting MS the OWIMS Study Neurology 53 1999 679 686
6. D. Francis Use of drugs to alter disease course A. Thompson I. McDonald Key advances in the effective management of multiple sclerosis 1999 Royal Society of Medicine Press London 31 35
7. N. Grigoriadis Interferon β treatment in the relapse-remitting multiple sclerosis Clin Neurol Neurosurg 104 2002 251 258
8. G. Antonelli, F. Dianzani Development of antibodies to interferon beta in patients technical and biological aspects Eur Cytokine Netw 10 1999 413 422
9. G. Giovannoni, F.E. Munschauer, F. Deisenhammer Neutralising antibodies to interferon beta during the treatment of multiple sclerosis J Neurol Neurosurg Psychiatry 73 2002 465 469
10. I.M. Kerr, G.R. Stark The control of interferon-inducible gene expression FEBS Lett 285 1991 194 198
11. D.E. Levy, D.S. Kessler, R. Pine, N. Reich, J.E. Darnell Jr Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control Genes Dev 2 1988 383 393
12. B.R.G. Williams Transcriptional regulation of interferon-stimulated genes Eur J Biochem 200 1991 1 11
13. L.C. Platanias, E.N. Fish Signaling pathways activated by interferons Exp Hematol 27 1999 1583 1592
14. I.M. Wang, J.C.G. Blanco, S.Y. Tsai, M.J. Tsai, K. Ozato Interferon regulatory factors and TFIIB cooperatively regulate interferon-responsive promoter activity in vivo and in vitro Mol Cell Biol 16 1996 6313 6324
15. C.M. Poser, D.W. Paty, L. Scheinberg, W.I. McDonald, F.A. Davis, G.C. Ebers New diagnostic criteria for multiple sclerosis guidelines for research protocols Ann Neurol 13 1983 227 231
16. E. Waubant, S. Vukusic, L. Gignoux, F. Durand-Dubief, I. Achiti, S. Blanc Clinical characteristics of responders to interferon therapy for relapsing MS Neurology 61 2003 184 189
17. R.A. Rudick, J.C. Lee, J. Simon, R.M. Ransohoff, E. Fisher Defining interferon beta response status in multiple sclerosis patients Ann Neurol 56 2004 548 555
18. G. Antonelli, F. Bagnato, C. Pozzilli, E. Simeoni, S. Bastianelli, M. Currenti Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a J Interferon Cytokine Res 18 1998 345 350
19. A. Bansal, D. van den Boom, S. Kammerer, C. Honisch, G. Adam, C.R. Cantor Association testing by DNA pooling an effective initial screen Proc Natl Acad Sci U S A 99 2002 16871 16874
20. S.D. Mooney, R.B. Altman MutDB Annotating human variation with functionally relevant data Bioinformatics 19 2003 1858 1860
21. Mooney Lab. MutDB. Available from: URL:http://mutdb.org Accessed Nov 8, 2005.
22. Riva A, Kohane IS. A Web-based tool to retrieve human genome polymorphisms from public databases. In: Proceedings of the American Medical Informatics Association 2001 annual conference; Nov 3-7, 2001; Washington DC.
23. T. Hubbard, D. Andrews, M. Caccamo, G. Cameron, Y. Chen, M. Clamp Ensembl 2005 Nucleic Acids Res 33 2005 D447 D453
24. M. Rebhan, V. Chalifa-Caspi, J. Prilusky, D. Lancet GeneCards encyclopedia for genes, proteins and diseases 1997 Bioinformatics Unit and Genome Center, Weizmann Institute of Science Rehovot (Israel)
25. GeneCards. Available from: URL: http://www.genecards.org. Accessed Nov 8, 2005.
26. V. Matys, E. Fricke, R. Geffers, E. Gößling, M. Haubrock, R. Hehl TRANSFAC transcriptional regulation, from patterns to profiles Nucleic Acids Res 31 2003 374 378
27. Transfac. Databases. Available from: URL: http://www.biobase.de/pages/ products/databases.html. Accessed Nov 8, 2005.
28. Transcription regulatory regions database (TRRD). Available from: URL: www.bionet.nsc.ru/trrd/. Accessed Nov 8, 2005.
29. Kel A, Goessling E. MATCH. Available from: URL: Biobase GmbH, www.biobase.de.
30. T. Werner Computer-assisted analysis of transcription control regions. Matinspector and other programs Methods Mol Biol 132 2000 337 349
31. TESS: Transcription element search software. Available from: URL: www.cbil.upenn.edu/tess. Accessed Nov 8, 2005.
32. D.S. Prestridge SIGNAL SCAN A computer program that scans DNA sequences for eukaryotic transcriptional elements CABIOS 7 1991 203 206
33. B. Ewing, L. Hillier, M.C. Wendl, P. Green Base-calling of automated sequencer traces using phred. I. Accuracy assessment Genome Res 8 1998 175 185
34. B. Ewing, P. Green Base-calling of automated sequencer traces using phred. II. Error probabilities Genome Res 8 1998 186 194
35. G. Breen, D. Harold, S. Ralston, D. Shaw, D. St Clair Determining SNP allele frequencies in DNA pools Biotechniques 28 2000 464 470
36. B. Devlin, K. Roeder Genomic control for association studies Biometrics 55 1999 997 1004
37. P.C. Sham, D. Curtis Monte Carlo tests for associations between disease and alleles at highly polymorphic loci Ann Hum Genet 59 1995 97 105
38. B.S. Weir Genetic data analysis II methods for discrete population genetic data 1996 Sinauer Associates Sunderland (MA)
39. G.V. McDonnell, C.W. Kirk, D. Middleton, A.G. Droogan, S.A. Hawkins, C.C. Patterson Genetic association studies of tumour necrosis factor alpha and beta and tumour necrosis factor receptor 1 and 2 polymorphisms across the clinical spectrum of multiple sclerosis J Neurol 246 1999 1051 1058
40. H.A. Bluyssen, R.J. Vlietstra, A. Van der Made, J. Trapman The interferon-stimulated gene 54 K promoter contains two adjacent functional interferon-stimulated response elements of different strength, which act synergistically for maximal interferon-alpha inducibility Eur J Biochem 220 1994 395 402
41. Z. Xu, B.R. Williams Genomic features of human PKR alternative splicing and a polymorphic CGG repeat in the 5'-untranslated region J Interferon Cytokine Res 18 1998 609 616
42. U. Sriram, L.F. Barcellos, P. Villoslada, J. Rio, S.E. Baranzini, S. Caillier Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis Genes Immun 4 2003 147 152
43. J. Muldoon, A. Uriel, S. Khoo, W.E. Ollier, A.H. Hajeer Novel IFN-alpha receptor promoter polymorphisms Genes Immun 2 2001 159 160
44. L. Leyva, O. Fernandez, M. Fedetz, E. Blanco, V.E. Fernandez, B. Oliver IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response J Neuroimmunol 163 2005 165 171
45. Y. Sugimoto, N. Kuzushita, T. Takehara, T. Kanto, T. Tatsumi, T. Miyagi A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C J Viral Hepat 9 2002 377 384
46. F. Gilli, F. Marnetto, M. Caldano, A. Sala, S. Malucchi, A. Di Sapio Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis J Neuroimmunol 158 2005 195 203
47. F. Gilli, A. Sala, C. Bancone, P. Salacone, M. Gallo, E. Gaia Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients J Immunol Methods 262 2002 187 190
48. M. Hijikata, S. Mishiro, C. Miyamoto, Y. Furuichi, M. Hashimoto, Y. Ohta Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro Intervirology 44 2001 379 382
49. J.K. King, S.H. Yeh, M.W. Lin, C.J. Liu, M.Y. Lai, J.H. Kao Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients a pilot study Hepatology 36 2002 1416 1424
50. H. Nakanishi Microglial functions and proteases Mol Neurobiol 27 2003 163 176
51. H. Beck, G. Schwarz, C.J. Schroter, M. Deeg, D. Baier, S. Stevanovic Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro Eur J Immunol 31 2001 3726 3736
52. C. Driessen, R.A. Bryant, A.M. Lennon-Dumenil, J.A. Villadangos, P.W. Bryant, G.P. Shi Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells J Cell Biol 147 1999 775 790
53. J. Hong, Y.C. Zang, G. Hutton, V.M. Rivera, J.Z. Zhang Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis J Neuroimmunol 152 2004 126 139
54. F. Koike, J. Satoh, S. Miyake, T. Yamamoto, M. Kawai, S. Kikuchi Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis J Neuroimmunol 139 2003 109 118